Antimicrobials: New solutions badly needed - Editorial overview

Current Opinion in Microbiology

Volumn 5, Issue 5, 2002, Pages 463-465

  Projan, Steven J ^a   Youngman, Philip J ^b  

^a WYETH RESEARCH   (United States)

^b Elitra Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CIPROFLOXACIN; DOXYCYCLINE; PROTEIN; RNA; VACCINE; VANCOMYCIN; VIRULENCE FACTOR;

ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACILLUS ANTHRACIS; BIOFILM; COST; DRUG INDUSTRY; ECONOMICS; EPIDEMIC; FRANCISELLA TULARENSIS; GENOMICS; HUMAN; NONHUMAN; POLYMERASE CHAIN REACTION; SHORT SURVEY; STAPHYLOCOCCUS AUREUS; YERSINIA PESTIS;

ANTHRAX; BACILLUS ANTHRACIS; FRANCISELLA TULARENSIS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; YERSINIA; YERSINIA PESTIS;

EID: 0036792157     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1369-5274(02)00364-8     Document Type: Editorial

References (5)

1. Centers for Disease Control: Staphylococcus aureus resistant to vancomycin - United States, 2002. Morbid Mortal Weekly Rep 2002, 51:565-567.
2. Begley S, Bryant M: The end of antibiotics? Newsweek, March 7 1994.
3. IMS Health: MIDAS Report, May 15 2002.
4. Youngman P: Approaches to new antimicrobial targets in the age of genomics. In Bacterial Resistance to Antimicrobials. Edited by K Lewis et al. New York: Marcel Dekker, 2002:455-478.
5. Tufts Center for the Study of Drug Development. Backgrounder: How New Drugs Move Through the Drug Development and Approval Process. Tufts University, November 1 2001.